Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
TG Therapeutics, Inc. clinical trials
The registry lists 44 studies whose lead sponsor is TG Therapeutics, Inc. or one of 1 company grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the TG Therapeutics, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to TG Therapeutics, Inc..
Focus areas
Conditions TG Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 44 of 44.
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabRecruitingNCT05877963Phase 3
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)RecruitingNCT06433752
- Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With SchizophreniaRecruitingNCT07680946Phase 2
- A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)RecruitingNCT07673744Phase 2
- A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)RecruitingNCT06433765
- A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)RecruitingNCT07503873Phase 2
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisRecruitingNCT07220252Phase 2/3
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersRecruitingNCT06680037Phase 1
- Long-term Follow-up (LTFU) of Participants Who Received Azer-CelNot yet recruitingNCT07577583
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)Active, not recruitingNCT07211633Phase 3
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast MilkActive, not recruitingNCT06143514
- An Extension Study of Ublituximab in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT04130997Phase 3
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedNCT02612311Phase 3
- Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTerminatedNCT04806035Phase 1
- Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell MalignanciesTerminatedNCT03671590Phase 1
- Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedNCT02742090Phase 2
- Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)TerminatedNCT03801525Phase 2/3
- Study of TG-1801 in Subjects With B-Cell LymphomaCompletedNCT03804996Phase 1
- Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular LymphomaTerminatedNCT03828448Phase 2
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2
- Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's LymphomaCompletedNCT03364231Phase 2
- A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304TerminatedNCT02656303Phase 2
- An Extension of the TG1101-RMS201 TrialCompletedNCT03381170Phase 2
- Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedNCT01647971Phase 1/2
- Ublituximab + Ibrutinib in Select B-cell MalignanciesCompletedNCT02013128Phase 1/2
- Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's TransformationCompletedNCT02535286Phase 1
- Study of Cosibelimab in Subjects With Relapsed or Refractory LymphomaTerminatedNCT03778073Phase 1
- Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHLTerminatedNCT03379051Phase 1/2
- Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins LymphomaTerminatedNCT02793583Phase 2/3
- Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 TrialsTerminatedNCT03207256Phase 2
- Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)CompletedNCT02301156Phase 3
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)CompletedNCT03277248Phase 3
- Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )CompletedNCT03277261Phase 3
- Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01767766Phase 1
- Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple SclerosisCompletedNCT02738775Phase 2
- Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell MalignanciesCompletedNCT02006485Phase 1
- TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid TumorsCompletedNCT02574663Phase 1
- TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02100852Phase 1
- Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma PatientsCompletedNCT02164006Phase 1
- A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate PsoriasisCompletedNCT00593177Phase 2
Sponsor listed in the registry: Manhattan Pharmaceuticals
- Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of MigraineStatus unknownNCT00285402Phase 2
Sponsor listed in the registry: Ariston Pharmaceuticals, Inc. · First submitted before Ariston Pharmaceuticals, Inc. became part of TG Therapeutics, Inc.
- Phase 2a Randomized, Double-Blind Study of Oleoyl-Estrone in Male Morbidly Obese AdultsStatus unknownNCT00449254Phase 2
Sponsor listed in the registry: Manhattan Pharmaceuticals
- Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)Status unknownNCT00449202Phase 2
Sponsor listed in the registry: Manhattan Pharmaceuticals